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Summary.-This report compares the results at 36 months for 121 patients treated
with radiotherapy alone (R) and 115 with radiotherapy followed by 3-drug chemo-
therapy (RC) for small-cell carcinoma of the lung of "limited" extent.
The RC patients had an increased survival (P=0.009 by log-rank test). The median
survival was 25 weeks for the R patients and 43 weeks for the RC patients, but at 36
months, only 4 (3oo) of the R patients and 5 (4%0) of the RC patients were still alive.
There was evidence of recurrence of the primary cancer in41 (35%) ofthe 117 R and
35 (32%) of the 110 RC patients who died. Distant metastases were more frequent in
the R series, being reported in 99 (82o%) compared with 82 (71%) of the RC patients
(P<0-05 by log-rank test). The numbers of R patients alive and considered free of
metastases were 10 (8%/) at 12 months, 3 (2o%) at 24 months and 3 (2%) at 36 months;
the corresponding figures for the RC patients being 30 (26%), 9 (8%), and 4 (3%).
SMALL-CELL CARCINOMA of the lung is
usually treated by non-surgical methods.
It is very sensitive to radiation and
chemotherapy, and current management
usually includes both (Hansen, 1980;
Oldham & Greco, 1980). Although survival
has been improved, the best drug combina-
tions and the best ways of using radiation
therapy still remain to be defined.
The present study, to which patients
were admitted between March 1975 and
April 1977, was designed to compare radio-
therapy alone (R) with radiotherapy
followed by chemotherapy with cyclo-
phosphamide, methotrexate and CCNU
(RC). The main findings at 12 months
(MRC Lung Cancer Working Party, 1979)
were that in the RC series, there was a
significantly increased survival (P=0-002
by log-rank test) distant metastases
appeared later and less frequently, but
adverse reactions weremuchmore frequent
and severe. In this report the results on all
patients up to a minimum of 3 years are
presented.
PLAN AND CONDUCT OF THE STUDY
The plan and conduct of the study were
described in detail in the first report (MRC
Lung Cancer Working Party, 1979). The
main points are summarized below%N.
Eligibility
Patients aged 70 years or less were eligible
if they had a previously untreated histo-
logically or cytologically proven small-cell
carcinoma (Kreyberg et al., 1967) confined to
the soft tissues of one hemithorax and the
ipsilateral and contralateral scalene and
lower cervical nodes, the cell type being con-
firmed by a single reference pathologist.
Requiests for reprints to Miss J. S. Lea(lbeater, Ae(lical Research Council, 20 Park Crescent, Londlon
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Treatment
Patients were randomly allocated to treat-
ment with either radiotherapy alone (R), or
radiotherapy followed by 3-drug chemo-
therapy (RC).
Radiotherapy consisted of a megavoltage
midline dosage of 30 Gy given in 15 fractions
over 3 weeks, or a suitable biological equiva-
lent. There was an interval of 3 weeks
between the end of the radiotherapy and the
first pulse ofchemotherapy.
Chemotherapy consisted of 10 alternating
3-drug and 2-drug pulses at 3-week intervals,
though it could be stopped before the com-
pletion of 10 pulses or prolonged beyond 10
pulses if the patient's progress warranted it.
Cyclophosphamide (500 mg/M2) plus metho-
trexate (50 mg/M2) were given by i.v. injec-
tion on each occasion, 10 mg of ineto-
clopramide being included as an anti-emetic.
CCNU (50 mg/Mi2) was given orally on the
first and alternating pulses thereafter. that is
every 6 weeks for 5 pulses.
Reports and investigations
A report on each patient was completed
pretreatment, at each attendance for treat-
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ment, monthly up to 18 months and then
once every 3 months. These reports included
information on the allocated therapy, addi-
tional palliative therapy, any adverse reac-
tions encountered, and metastases.
RESULTS
A total of 253 patients were admitted
from 16 centres in the U.K.; 17 were
excluded (MRC Lung Cancer Working
Party, 1979), leaving 236 (121 R, 115 RC)
for analysis.
Condition on admission
The details of the patients' condition
on admission were given in the first report
(MRC Lung Cancer Working Party, 1979).
The majority (72%) were male, 66% were
aged 55-70 years, 58% were considered by
their physician to be in "good" clinical
condition, 51% were capable of normal or
nearly normal activity (activity grades
1 or 2) and the respiratory assessment was
-RRC
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normal or nearly normal (grades I or 2) in
50°0.
Survival
The survival curves (Fig.) show no
difference up to the end of the first 3
months (well after the end of the course
of radiotherapy). Thereafter there was
increased survival in the RC series (P=
0 009, log-rank test). At 12 months 22
(818%) of the 121 R patients were alive
(95%0 confidence limits 12-26oo), conmpared
with 39 (34o%) of the 115 RC patients
(limits 25-43%) (P=0009). However, at
36 months the corresponding figures were
only 4 (3%0) and 5 (4%0) respectively.
The median survival was 25 weeks for the
R patients (limits 22-34) and 43 weeks
for the RC patients (limits 34-48).
Of the 4 R patients alive at 36 months,
I died with metastases at 39 months, 1 is
alive at 63 months, but with metastases,
and 2 are alive, well and with no evidence
of recurrence at 61 and 62 months, respec-
tively. Of the 5 RC patients alive at 36
months, 2 died, 1 at 37 months with meta-
stases, the other of cor pulmonale at 52
months with no evidence of cancer, 1 is
alive at 53 months, but with metastases,
and 2 are alive, well and with no evidence
of recurrence at 38 and 50 months, respec-
tively.
Proynosticfactors
Age, weight, haemoglobin concentra-
tion, total white cell and platelet counts,
clinical condition, grade of activity and
respiratory assessment on admission, and
sex were examined singly and in combina-
tion, using stratification of the log-rank
test (Peto et at., 1977) for their relationship
to survival. The only factors found to be
significantly related were age (P= 0-03)
and clinical condition (P = 0.03). None of
the factors affected the comparison be-
tween the R and RC series.
Evidence ofprimary growth at death
There was clinical or radiographic
evidence of persistence, extension or
recurrence of the primary cancer in 41
(35%0) of the 117 R and 35 (32%) of the
110 RC patients who died during the 36
months. Such evidence was confirmed in
14 of the 18 R and 15 of the 24 RC
patients who had a necropsy, but of these
29 patients, 22 (11 in each series) also had
distant metastases.
Metastases
The Table shows the frequency ofmeta-
stasesduringthe36 months; 82% ofthe 121
TABLE. Cumulative occurrence and site af
distant metastases during 36 months
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R and 71% of the 115 RC patients de-
veloped clinical evidence of distant meta-
stases (P < 0 05 by log-rank test), a smaller
difference than at 12 months, when the
corresponding proportions were 79%0 and
57%0 (P=0 0005). All the patients with
metastases except 2 (both RC) had their
metastases diagnosed during the first 24
months. The differences between the series
for individual sites were small. At 12
months 10 (8%) of the R and 30 (26%)
of the RC patients were alive and con-
sidered to be free of metastases, at 24
months 3 (2%) and 9 (8%), respectively,
and at 36 months 3 (2%) and 4 (3%0)
respectively.
Modification.s to cheniotherapy in the RC
series
Of the 101 RC patients who started
their prescribed chemotherapy, 33 (33%0)
receiveditwithoutmodification, 19ofthem
completing the course and 14 dying
during the course. A further 30 (30o%)
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had 1 or more doses omitted, delayed or
modified because of adverse reactions, 19
of them eventually completing the course.
The remaining 38 (38%) did not complete
the planned course of chemotherapy, 22
because of adverse reactions, 15 because
it was considered that the disease was not
responding, and 1 because of default.
A total of 12 patients were still receiving
the prescribed chemotherapy at 12 months
because their disease was still considered
to be responding. Chemotherapy was
eventually stopped after the 12-month
dose for 1 of these 12 patients, at 14
months for 3, at 16 months for 2, and at
17, 18, 20, 23, 26 and 27 months for the
remaining 6 respectively. Ofthe 12, 4 died
while still receiving chemotherapy. Of the
remaining 8, 3 were alive at 36 months
having received 16, 23 and 27 months of
chemotherapy, respectively; 1 ofthe 3 died
at 37 months, the other 2 are alive at 50
and 53 months respectively, the first with
no evidence of recurrence, the second with
metastases.
Additional palliative treatment
Of the 117 R and 109 RC patients who
completed the prescribed radiotherapy,
60 (51%0) of the R patients were given
additional palliative therapy during the
first 12 months, compared with 21 (19%o)
of the RC patients. For the 60 R patients,
this was chemotherapy alone for 17 (15%),
radiotherapy alone for 25 (21%), and
radiotherapy and chemotherapy for the
remaining 18 (15%). For all 21 of the RC
patients it was radiotherapy alone.
During the second year a further 2 R
patients had additional palliative treat-
ment (one radiotherapy, the other radio-
therapy and chemotherapy) as did 7 RC
patients (1 radiotherapy, 6 radiotherapy
and chemotherapy). During the third year,
2 other RC patients had palliative treat-
ment (one radiotherapy, the other radio-
therapy and chemotherapy). Thus, during
the 36 months, a total of 62 (530o) of the
R patients were given additional palliative
treatment, compared with 30 (28%) ofthe
RC patients (P = 00002).
Adverse reactions
The adverse reactions reported during
the first 12 months were described in
detail in the first report (MRC Lung Can-
cer Working Party, 1979). In summary,
38 (32%) of the 118 R and 93 (83%) of
the 112 RC patients who started treatment
had adverse reactions, either to their
allocated therapy or to palliative therapy,
during the first 12 months (P < 00001 ).
The commonest reactions were nausea and
vomiting, which occurred in 15 (13%) of
the R and 79 (71%) of the RC patients (P
< 0-0001), and haematological reactions
which occurred in 27 (23%) and 60 (540o)
respectively (P < 0 0001).
Only one patient in each series had any
evidence of an adverse reaction for the
first time after 12 months. The R patient
had a total white cell count of 2200/mm3
in the 25th month during palliative
chemotherapy, and the RC patient had a
platelet count of 98,000 in the 23rd month,
while still receiving the allocated chemo-
therapy which had been continued without
a break, but which was then stopped.
DISCUSSION
There have been definite achieveements
in the management ofsmall-cell carcinoma
of the lung over the past few years. An
optimistic assessment of the current
situation suggests that up to 25% of
patients with limited-stage disease may
survive to 2 years as a result of intensive
therapy (Oldham & Greco, 1.980). How-
ever, the great majority of patients still
die of their disease, often very rapidly.
The results of this study are clearly not
as good as the best reported (reviewed by
Hansen, 1980). There are probably several
reasons for this, some ofwhich are obvious
and others are hypothetical. They include
the extent of disease when treatment is
started, and the choice ofradiotherapy and
chemotherapy regimens, and the sequence
in which they are given. Age and clinical
condition on admission influenced prog-
nosis in the present study. Age has not
consistently been found to influence prog-
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nosis in other studies; its influence was not
great in the present study (P= 0.03), so
may have been a chance finding. Initial
clinical condition probably correlates more
closely with extent of disease, and other
studies have reported an association
between survival and clinical assessments.
The use of radiotherapy in the manage-
ment of local disease has been general
practice until recently (reviewed by Blee-
hen, 1979; Salazar & Creech, 1980; Han-
sen, 1980). The first MRC small-cell study
(Fox & Scadding, 1973) demonstrated the
superior results of radiotherapy alone
over those of surgery alone, though this
conclusion has subsequently been ques-
tioned (Levison, 1980) for a very selected
series of patients whose disease is con-
sidered to be sufficiently localized for
them to be treated with radiotherapy
followed by surgery (usually pneumon-
ectomy).
The radiation dosage to the local
disease has varied very considerably in
different series. Thus Salazar & Creech
(1980) quote a mean total dosage of 45 Gy
(range 42-55 Gy) in 446 patients treated
by 10 different groups. The dosage selected
for the present study was considerably
lower, and was chosen in a deliberate
attempt to keep radiation morbidity to a
minimum, while permitting chemotherapy.
The fact that about one third of all the
patients treated in this study had clinical
or radiographic evidence of persistence,
extension or recurrence of the primary
tumour, suggests thatthisradiation dosage
was inadequate. However, there is little
evidence in well conducted controlled
studies, that higher radiation dosages do
in fact improve local control or survival
(reviewed by Bleehen, 1979, and by Han-
sen et al., 1980). Also, in the present study,
most of the patients with evidence of
cancer at the primary site at death, had
distant metastases; it is therefore doubtful
whether a higher radiation dosage would
have improved the results.
Radiotherapy has also been advocated
as a method of controlling occult metas-
tasis. This may involve whole-body or
hemi-body irradiation (Dawes, 1980; Sala-
zar et al., 1980) or, more usually, elective
radiation to common metastatic sites, in
particular the brain (Johnson et al., 1976;
Livingston, 1979; Hansen, 1980). While
there is evidence that the incidence of
CNS metastases may be reduced by such
procedures, there is no evidence in ran-
domized studies ofan associated prolonga-
tion of survival (Hansen, 1980).
The choice of the chemotherapy regi-
men has been discussed in the first report
on this present study (MRC, 1979) and
was based on the report by Hansen et al.
(1976) of its efficacy. The results of the
present study confirm its activity, in that
its addition to the radiotherapy signifi-
cantly improved survival. However, the
inclusion of the drug CCNU was regarded
unfavourably by many patients and their
clinicians because of the associated side
effects. The absence of any reduction in
the incidence ofCNS metastases has raised
questions about its ability to control them.
Numerous other chemotherapy regi-
mens have been reported, with varying
results (Hansen, 1980; Oldham & Greco,
1980). Of relevance to the present report
are the results of a randomized trial by
Hansen et al. (1980) using a very similar
drug regimen and a not dissimilar total
radiation dosage. Their staging investiga-
tions were more rigorous, and are therefore
likely to have allowed the inclusion of a
smaller proportion of patients with un-
recognized "extensive" disease than in the
present study, in which isotopic scans,
marrow examination and peritoneoscopy
were not mandatory. The median duration
of survival reported by Hansen et al.
(1980) was, however, very similar to that
reported here, namely 310 days compared
with 300 days (43 weeks), and the propor-
tion ofpatients alive at 18 months was the
same (13O% in both series). It is of interest
that no improvement in survival was seen
by the Danish group when they added
irradiation ofthe brain, adrenals andupper
retroperitoneal lymph nodes.
Better results, but in much smaller series
of patients, have been reported, with a
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2-year survival of 25% (Oldham &
Greco, 1980). If differences in patient
selection are not the main or only reason
for this difference, our failure to achieve
suchresultsmaythenrelate tothe choice of
chemotherapy regimen. Evidence for this
may be deduced from the study reported
by Cohen et al. (1977) in which the 3-drug
regimen (cyclophosphamide, methotrexate
and CCNU) at similar dosages was com-
pared with the same drugs given at
approximately double dosages. Toxicity
was considerably greater with the higher
dosages, but so was the median survival.
Other drugs with activity against small-
cell lung cancer such as vincristine,
Adriamycin, and the podophyllin deriva-
tives, VP16-213 and VM26, are now being
included in various combinations, and may
produce better maintained survival.
In the present study, the sequence in
which the two treatment modalities were
combined was selected with the aim of
controlling local disease with radiotherapy
first before giving systemic treatment to
occult disease. This sequence might be
criticised as permitting the early develop-
ment of metastases during the 6 weeks
before chemotherapy. Data in favour of
this concept have been reviewed (Bleehen,
1980; Salazar & Creech, 1980) but are
inconclusive. This question of drug-
radiation sequence is being formally
tested in the current (3rd) MRC small-cell
study, and in a Swiss study (Alberto,
personal communication).
Finally, the necessity for radiotherapy
in the primary management of the disease
is now being questioned (reviewed by
Hansen, 198C). In 2 large randomized
series of patients (total 259) median sur-
vival was not improved by the addition of
radiotherapy to the selected drug regimens
(Hansen et al., 1979; Fox et al., 1980). It
may well be that, with further improve-
ments in chemotherapy, radiotherapy will
have no place in the primary treatment.
Alternatively, improved radiation therapy
with radiosensitizers or particle therapy
may, in the future, produce better control
of local disease and enhance the systemic
results of improved chemotherapy. Both
these possibilities remain a matter for
speculation. At present, the results of
treating small-cell carcinoma of the lung
remain poor, and considerably more effort
with carefully documented randomized
studies, after innovative pilot studies, is
required.
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